

# Shelley Zieroth

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5337062/publications.pdf>

Version: 2024-02-01

45  
papers

2,077  
citations

430874

18  
h-index

254184

43  
g-index

45  
all docs

45  
docs citations

45  
times ranked

2846  
citing authors

#	ARTICLE	IF	CITATIONS
1	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. <i>Nature Medicine</i> , 2022, 28, 568-574.	30.7	341
2	Polymorphic Ventricular Tachycardia Detected With a Smartwatch. <i>CJC Open</i> , 2022, 4, 424-427.	1.5	3
3	Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. <i>International Journal of Cardiology</i> , 2021, 327, 138-145.	1.7	19
4	Trends, management and outcomes of acute myocardial infarction in chronic liver disease. <i>International Journal of Clinical Practice</i> , 2021, 75, e13841.	1.7	3
5	Automated E-Counseling for Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007073.	3.9	13
6	Establishing a Cardiac Amyloidosis Clinic: A Practical Primer for Cardiologists. <i>Canadian Journal of Cardiology</i> , 2021, 37, 674-678.	1.7	2
7	National Trends of Gender Disparity in Canadian Cardiovascular Society Guideline Authors, 2001-2020. <i>CJC Open</i> , 2021, 3, S12-S18.	1.5	7
8	CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2021, 37, 531-546.	1.7	170
9	Hyperkalaemia in Heart Failure. <i>Cardiac Failure Review</i> , 2021, 7, e10.	3.0	4
10	Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?. <i>Current Opinion in Cardiology</i> , 2021, 36, 672-681.	1.8	9
11	Long COVID-19: A Primer for Cardiovascular Health Professionals, on Behalf of the CCS Rapid Response Team. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1260-1262.	1.7	16
12	Characteristics of Clinicians Are Associated With Their Beliefs About ICD Deactivation: Insight From the DECIDE-HF Study. <i>CJC Open</i> , 2021, 3, 994-1001.	1.5	1
13	Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats. <i>Molecules</i> , 2021, 26, 5006.	3.8	11
14	Are post-hoc analyses on subgroups sufficient to support new treatment algorithms of heart failure? The case of SGLT2 inhibitors associated with sacubitril/valsartan. <i>Cardiology</i> , 2021, , .	1.4	2
15	A Comprehensive Analysis of the Efficacy of Resveratrol in Atherosclerotic Cardiovascular Disease, Myocardial Infarction and Heart Failure. <i>Molecules</i> , 2021, 26, 6600.	3.8	22
16	Adequate Decongestion Is Still the Question in Heart Failure. <i>Cardiology</i> , 2021, 146, 60-62.	1.4	0
17	The Hospital Frailty Risk Score and its association with in-hospital mortality, cost, length of stay and discharge location in patients with heart failure short running title: Frailty and outcomes in heart failure. <i>International Journal of Cardiology</i> , 2020, 300, 184-190.	1.7	48
18	HEARTBIT: A Transcriptomic Signature for Excluding Acute Cellular Rejection in Adult Heart Allograft Patients. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1217-1227.	1.7	11

#	ARTICLE	IF	CITATIONS
19	Hyperkalemia in heart failure. <i>Current Opinion in Cardiology</i> , 2020, 35, 150-155.	1.8	17
20	Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada. <i>CJC Open</i> , 2020, 2, 321-327.	1.5	8
21	Sex, Gender, and Equity in Cardiovascular Medicine, Surgery, and Science in Canada: Challenges, Successes, and Opportunities for Change. <i>CJC Open</i> , 2020, 2, 522-529.	1.5	14
22	Optimizing Access to Heart Failure Care in Canada During the COVID-19 Pandemic. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1148-1151.	1.7	19
23	Canadian Cardiovascular Society/Canadian Cardiac Transplant Network Position Statement on Heart Transplantation: Patient Eligibility, Selection, and Post-Transplantation Care. <i>Canadian Journal of Cardiology</i> , 2020, 36, 335-356.	1.7	33
24	The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey. <i>CJC Open</i> , 2020, 2, 151-160.	1.5	10
25	Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020, 36, 322-334.	1.7	68
26	CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020, 36, 159-169.	1.7	89
27	Relation of Increasing QRS Duration Over Time and Cardiovascular Events in Outpatients With Heart Failure. <i>American Journal of Cardiology</i> , 2019, 124, 1907-1911.	1.6	8
28	Comparative effectiveness of the different components of care provided in heart failure clinicsâ€”protocol for a systematic review and network meta-analysis. <i>Systematic Reviews</i> , 2019, 8, 40.	5.3	4
29	The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 904.	4.1	116
30	Are the cardioprotective effects of the phytoestrogen resveratrol sex-dependent?. <i>Canadian Journal of Physiology and Pharmacology</i> , 2019, 97, 503-514.	1.4	14
31	Multicenter evaluation of a national organ sharing policy for highly sensitized patients listed for heart transplantation in Canada. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 491-498.	0.6	24
32	Primary Percutaneous Coronary Intervention As Treatment for ST-Elevation Myocardial Infarction in a Centenarian: Choosing Carefully. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1066.e1-1066.e3.	1.7	3
33	The Need for Heart Failure Advocacy in Canada. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1450-1454.	1.7	25
34	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1342-1433.	1.7	503
35	Barriers to Goals of Care Discussions With Patients Who Have Advanced Heart Failure: Results of a Multicenter Survey of Hospital-Based Cardiology Clinicians. <i>Journal of Cardiac Failure</i> , 2017, 23, 786-793.	1.7	33
36	Peripartum Cardiomyopathy Characteristics and Outcomes in Canadian Aboriginal and Non-Aboriginal Women. <i>Canadian Journal of Cardiology</i> , 2017, 33, 471-477.	1.7	6

#	ARTICLE	IF	CITATIONS
37	Diagnosis of Left Ventricular Assist Device Outflow Graft Obstruction Using Intravascular Ultrasound. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	7
38	Resveratrol is equipotent to perindopril in attenuating post-infarct cardiac remodeling and contractile dysfunction in rats. <i>Journal of Nutritional Biochemistry</i> , 2016, 28, 155-163.	4.2	24
39	The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice. <i>Canadian Journal of Cardiology</i> , 2016, 32, 296-310.	1.7	86
40	Acute Kidney Injury Following Percutaneous Coronary Intervention: Trying to Get Whole Eggs From an Omelette. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1221-1222.	1.7	0
41	An overview of the efficacy of resveratrol in the management of ischemic heart disease. <i>Annals of the New York Academy of Sciences</i> , 2015, 1348, 55-67.	3.8	41
42	The Urea-to-Creatinine Ratio Is Predictive of Worsening Kidney Function in Ambulatory Heart Failure Patients. <i>Journal of Cardiac Failure</i> , 2015, 21, 412-418.	1.7	19
43	The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications. <i>Canadian Journal of Cardiology</i> , 2015, 31, 3-16.	1.7	96
44	The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Rehabilitation and Exercise and Surgical Coronary Revascularization. <i>Canadian Journal of Cardiology</i> , 2014, 30, 249-263.	1.7	44
45	Potential of resveratrol in the treatment of heart failure. <i>Life Sciences</i> , 2014, 95, 63-71.	4.3	84